Le navigateur que vous utilisez n’est pas pris en charge.
Il est possible que certaines fonctionnalités de ce site ne s’affichent pas correctement. Pour une expérience de navigation optimale, veuillez consulter ce site dans Chrome, Firefox, Safari ou Edge.

Congrès

Documents du congrès

Accéder aux résumés, posters et présentations présentés aux congrès suivants

Mars 2023

American Society for Clinical Pharmacology & Therapeutics (ASCPT)

Mars 2023

Francophone Days of Hepato-gastroenterology and Digestive Oncology (Journées francophones d’hépato-gastroentérologie et d’oncologie digestive) (JFHOD)

Mars 2023

Japanese Society of Medical Oncology (Société japonaise d’oncologie médicale) (JSMO)

Février 2023

International Congress on Hematologic Malignancies: Focus on Leukemias, Lymphomas, and Myeloma (ICHM )

Février 2023

American Society of Clinical Oncology - Genitourinary Cancers Symposium (Société américaine d’oncologie clinique - Symposium des cancers urogénitaux) (ASCO-GU)

American Society of Clinical Oncology - Genitourinary Cancers Symposium (Société américaine d’oncologie clinique - Symposium des cancers urogénitaux) (ASCO-GU)

February 2023 (San Francisco, California, USA)
Février 2023

Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR (Tandem)

Janvier 2023

American Society of Clinical Oncology - Gastrointestinal Cancers Symposium (Société américaine d’oncologie clinique - Symposium des cancers gastro-intestinaux) (ASCO-GI)

American Society of Clinical Oncology - Gastrointestinal Cancers Symposium (Société américaine d’oncologie clinique - Symposium des cancers gastro-intestinaux) (ASCO-GI)

January 2023 (San Francisco, California, USA)
Décembre 2022

American Society of Hematology (Société américaine d’hématologie) (ASH)

American Society of Hematology (Société américaine d’hématologie) (ASH)

December 2022 (New Orleans, Louisiana, USA)

Résumés

A phase 1 study evaluating safety, tolerability, pharmacokinetics, and preliminary antitumor activity of Bcl-2 inhibitor BGB-11417 in adult patients with mature B-cell malignancies: preliminary data A phase 1 study with the novel B-cell lymphoma 2 (Bcl-2) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib (zanu) in patients (pts) with non-Hodgkin lymphoma or Waldenström macroglobulinemia (WM): preliminary data A phase 1 with the novel B-cell lymphoma 2 (Bcl-1) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib (zanu) in patients (pts) with CLL/SLL: preliminary data Biomarker analysis of zanubrutinib and tislelizumab combination therapy in patients with relapsed/refractory B-cell malignancies Development of hypertension and atrial fibrillation following diagnosis of B-cell malignancies - a retrospective analysis of US MarketScan insurance claims database Efficacy and safety of zanubrutinib in Japanese patients with mature B-cell malignancies Genomic characterization of patients in a phase 2 study of zanubrutinib in BTK inhibitor-intolerant patients with relapsed/refractory B-cell malignancies Long-term efficacy and safety of zanubrutinib in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL): final analysis of the MAGNOLIA (BGB-3111-214) trial Long-term outcomes of second-line vs later-line zanubrutinib treatment in patients with relapsed/refractory MCL: an updated pooled analysis Preliminary safety and efficacy of BGB-11417, a novel Bcl-2 inhibitor, in combination with azacitidine in patients with acute myeloid leukemia (AML) Preliminary safety and efficacy of zanubrutinib in combination with lenalidomide in patients with relapsed/refractory diffuse large B-cell lymphoma Preliminary safety of a Bcl-2 inhibitor, BGB-11417, in patients with relapsed/refractory multiple myeloma harboring t(11,14): a non-randomized, open-label, phase 1b/2 study Real-world evidence (RWE) studies supported hematologic oncology United States Food and Drug Administration (US FDA) approval: what do they look like? Zanubrutinib demonstrates superior progression-free survival (PFS) compared with ibrutinib for treatment of relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL): results from final analysis of ALPINE randomized phase 3 study Zanubrutinib in acalabrutinib-intolerant patients (pts) with B-cell malignancies
Décembre 2022

European Society of Medical Oncology Immuno-Oncology (Société européenne d’oncologie médicale et d’immuno-oncologie) (ESMO-IO)

European Society of Medical Oncology Immuno-Oncology (Société européenne d’oncologie médicale et d’immuno-oncologie) (ESMO-IO)

Décembre 2022 (Genève, Suisse)
Décembre 2022

European Society for Medical Oncology-Asia (Société européenne d’oncologie médicale-Asie) (ESMO-Asie)

European Society for Medical Oncology-Asia (Société européenne d’oncologie médicale-Asie) (ESMO-Asie)

Décembre 2022 (Singapour)
Novembre 2022

Congrès allemand sur le cancer (DKK)

Novembre 2022

Association coréenne pour le cancer du poumon (Korean Association for Lung Cancer, KALC)

Novembre 2022

Society for Immunotherapy of Cancer (Société d’immunothérapie pour le cancer) (SITC)

Novembre 2022

Portuguese Society of Hematology (Société portugaise d’hématologie) (SPH)

Novembre 2022

International Society for Pharmacoeconomics and Outcomes Research - Europe (Société internationale de recherche en pharmacoéconomie et les résultats - Europe) (ISPOR-EU)

Novembre 2022

Chinese Society of Clinical Oncology (Société chinoise d’oncologie clinique) (CSCO)

Chinese Society of Clinical Oncology (Société chinoise d’oncologie clinique) (CSCO)

Novembre 2022 (Chine)

Résumés

Time to response and depth of response in non-squamous non-small cell lung cancer patients treated with tislelizumab plus chemotherapy as first line therapy: an exploratory analysis of RATIONALE-304 Tislelizumab versus docetaxel as second- or third-line therapy in previously treated patients with locally advanced non-small cell lung cancer: asian versus non-asian subgroup analysis of the RATIONALE-303 study RATIONALE-304: tislelizumab plus chemotherapy versus chemotherapy alone as first line treatment for nonsquamous non-small cell lung cancer in patients aged 65-75 years Safety, tolerability, and preliminary antitumor activity of sitravatinib plus tislelizumab in patients with unresectable locally advanced or metastatic hepatocellular carcinoma A matching-adjusted indirect comparison of tislelizumab versus camrelizumab as second-line treatment for patients with advanced or metastatic esophageal squamous cell carcinoma ASPEN: long-term follow-up results of a phase 3 randomized trial of zanubrutinib (ZANU) vs ibrutinib (IBR) in patients with Waldenström macroglobulinemia (WM) AdvanTIG-105: a phase 1 dose-verification study of ociperlimab in combination with tislelizumab in advanced solid tumors in Chinese patients AdvanTIG-105: phase 1b dose-expansion study of ociperlimab plus tislelizumab with chemotherapy in patients with metastatic squamous and nonsquamous non-small cell lung cancer AdvantTIG-105: phase 1b dose-expansion study of ociperlimab plus tislelizumab in patients with metastatic non-small cell lung cancer HERIZON-GEA-01: a phase 3 study of zanidatamab in combination with chemotherapy with or without tislelizumab in first-line human epidermal growth factor receptor 2 positive advanced or metastatic gastroesophageal adenocarcinoma Preliminary safety and efficacy of BGB-11417, a potent and selective B-cell lymphoma 2 (BCL2) inhibitor, in patients (pts) with acute myeloid leukemia (AML) Rationale-304: the association of tumor mutational burden with clinical outcomes of tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced nonsquamous non-small cell lung cancer SEQUOIA: results of a phase 3 randomized study of zanubrutinib versus bendamustine plus rituximab (BR) in patients with treatment-naïve (TN) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) Safety, tolerability, and preliminary antitumor activity of sitravatinib plus tislelizumab in patients with unresectable locally advanced or metastatic gastric cancer or gastroesophageal junction cancer The effects of tislelizumab treatment on the health-related quality of life of non-small cell lung cancer patients who progressed on a prior platinum-containing regimen Tislelizumab versus docetaxel in patients with previously treated advanced nonsquamous non-small cell lung cancer: subanalysis from the RATIONALE-303 phase 3 randomized clinical study Tislelizumab versus docetaxel in patients with previously treated advanced squamous non-small cell lung cancer: sub-analysis from phase 3 RATIONALE-303 randomized clinical study Tislelizumab versus docetaxel in previously treated advanced non-small cell lung cancer: final analysis of RATIONALE-303 Zanubrutinib plus obinutuzumab (ZO) vs obinutuzumab (O) monotherapy in patients (pts) with relapsed or refractory (R/R) follicular lymphoma (FL): primary analysis of the phase 2 randomized ROSEWOOD trial
Novembre 2022

Clinical Oncology Society of Australia (Société d’oncologie clinique d’Australie) (COSA)

Octobre 2022

Atelier international sur la macroglobulinémie de Waldenström (International Workshop on Waldenström's Macroglobulinemia, IWWM)

Atelier international sur la macroglobulinémie de Waldenström (International Workshop on Waldenström's Macroglobulinemia, IWWM)

Octobre 2022 (Madrid, Espagne)
Octobre 2022

Société japonaise d’oncologie clinique (Japan Society of Clinical Oncology, JSCO)

Octobre 2022

Lymphome, leucémie et myélome (LLM)

Octobre 2022

Société japonaise d’hématologie (Japanese Society of Hematology, JSH)

Société japonaise d’hématologie (Japanese Society of Hematology, JSH)

Octobre 2022 (Fukuoka, Japon)
Octobre 2022

German, Austrian, and Swiss Societies for Hematology & Medical Oncology (Sociétés allemandes, autrichiennes et suisses d’hématologie et d’oncologie médicale) (DGHO)

German, Austrian, and Swiss Societies for Hematology & Medical Oncology (Sociétés allemandes, autrichiennes et suisses d’hématologie et d’oncologie médicale) (DGHO)

Octobre 2022 (Vienne, Autriche)
Octobre 2022

Spanish Society of Hematology and Hemotherapy (Société espagnole d’hématologie et d’hématothérapie) (SEHH)

Spanish Society of Hematology and Hemotherapy (Société espagnole d’hématologie et d’hématothérapie) (SEHH)

Octobre 2022 (Barcelone, Espagne)
Septembre 2022

Society of Hematologic Oncology (Société d’oncologie hématologique) (SOHO)

Society of Hematologic Oncology (Société d’oncologie hématologique) (SOHO)

September 2022 (Houston, Texas, USA)
Septembre 2022

Italian Society of Hematology (Société italienne d’hématologie) (SIE)

Italian Society of Hematology (Société italienne d’hématologie) (SIE)

Septembre 2022 (Rome, Italie)
Septembre 2022

Société néo-zélandaise d’oncologie (New Zealand Society for Oncology, NZSO)

Société néo-zélandaise d’oncologie (New Zealand Society for Oncology, NZSO)

Septembre 2022 (Christchurch, Nouvelle-Zélande)
Septembre 2022

Hematology Society of Australia and New Zealand (Blood) [Société d’hématologie d’Australie et de Nouvelle Zélande (sang)]

Hematology Society of Australia and New Zealand (Blood) [Société d’hématologie d’Australie et de Nouvelle Zélande (sang)]

Septembre 2022 (Sydney, Australie)
Septembre 2022

European Society for Medical Oncology (Société européenne d’oncologie médicale) (ESMO)

European Society for Medical Oncology (Société européenne d’oncologie médicale) (ESMO)

Septembre 2022 (Paris, France)
Septembre 2022

Polish Society of Hematology and Transfusion Medicine (Société polonaise d’hématologie et de médecine transfusionnelle) (PTHiT)

Septembre 2022

Korean Society of Medical Oncology (KSMO)

Août 2022

World Congress on Lung Cancer (Congrès mondial sur le cancer du poumon) (WCLC)

Juillet 2022

Pan Pacific Lymphoma Conference (Conférence pan-Pacifique du lymphome) (PPLC)

Juin 2022

World Congress on Gastrointestinal Cancer (Congrès mondial sur le cancer gastrointestinal) (WCGI)

Juin 2022

Asian Oncology Society (Société asiatique d'oncologie) (AOS)

Juin 2022

European Hematology Association (Association européenne d’hématologie) (EHA)

European Hematology Association (Association européenne d’hématologie) (EHA)

Juin 2022 (Vienne, Autriche)

Posters

A phase 1 first‑In‑human study of BGB‑16673, a Bruton tyrosine kinase protein degrader, in patients with B‑cell malignancies (trial in progress) A phase 1 study with the novel BCL2 Inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with B-cell malignancies: preliminary data ASPEN: long‑term follow‑up results of a phase 3 randomized trial of zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia Health-related quality of life outcomes associated with zanubrutinib vs ibrutinib monotherapy in patients with relapsed/refractory (RR) CLL/SLL: results from the randomized phase 3 ALPINE trial Patient-reported outcomes from a phase 3 randomized study of zanubrutinib vs bendamustine plus rituximab (BR) in patients with treatment-naive (TN) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) Population-wide patterns of care in chronic lymphocytic leukemia in Australia: an analysis of the pharmaceutical benefits scheme data set Preliminary safety and efficacy of BGB‑11417, a potent and selective B‑cell lymphoma 2 (BCL2) inhibitor, in patients with acute myeloid leukemia Real world evidence of impact of atrial fibrillation on clinical and economic outcomes in patients with chronic lymphocytic leukemia Real-world treatment patterns and comparative effectiveness of Bruton tyrosine kinase inhibitors in patients with mantle cell lymphoma Real-world treatment patterns and economic burden of patients with marginal zone lymphoma Results of a phase 2 expanded access study of zanubrutinib in patients with Waldenström macroglobulinemia Tislelizumab, a PD‑1 inhibitor for relapsed/refractory mature (NK)/T‑cell neoplasms: results from a phase 2 study Zanubrutinib in older patients with relapsed/refractory marginal zone lymphoma (MZL): subgroup analysis of the Magnolia study

Résumés

A phase 1 first in-human study of BGB-16673, a Bruton tyrosine kinase protein degrader, in patients (pts) with B-cell malignancies (trial in progress) A phase 1 study with the novel B-cell lymphoma 2 (BCL2) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib (zanu) in patients (pts) with B-cell malignancies: preliminary data Efficacy of first-line treatment for chronic lymphocytic leukemia: a bayesian network meta-analysis Health-related quality of life outcomes associated with zanubrutinib vs ibrutinib monotherapy in patients with relapsed/refractory (RR) CLL/SLL: results from the randomized phase 3 ALPINE trial Network meta-analysis of progression free survival in the treatment of relapsed or refractory chronic lymphocytic leukemia Patient-reported outcomes from a phase 3 randomized study of zanubrutinib versus bendamustine plus rituximab (BR) in patients with treatment-naïve (TN) CLL/SLL Population-wide patterns of care in chronic lymphocytic leukemia in Australia: an analysis of the pharmaceutical benefits scheme dataset Population-wide patterns of care in mantle cell lymphoma in Australia: an analysis of the pharmaceutical benefits scheme dataset Preliminary safety and efficacy of BGB-11417, a potent and selective B-cell lymphoma 2 (BCL2) inhibitor, in patients (pts) with acute myeloid leukemia (AML) Real world evidence of impact of atrial fibrillation on clinical and economic outcomes in patients with chronic lymphocytic leukemia Real-world treatment patterns and comparative effectiveness of Bruton tyrosine kinase inhibitors in patients with mantle cell lymphoma Real-world treatment patterns and economic burden of patients with marginal zone lymphoma Results of a phase 2 expanded access study of zanubrutinib in patients with Waldenström macroglobulinemia Treatment persistence and adherence to ibrutinib in patients with Waldenstrӧm macroglobulinemia: a German claims data analysis Zanubrutinib in acalabrutinib-intolerant patients (pts) with B-cell malignancies Zanubrutinib in older patients (pts) with relapsed/refractory (R/R) marginal zone lymphoma (MZL): subgroup analysis of the MAGNOLIA study
Juin 2022

American Society of Clinical Oncology (Société américaine d’oncologie clinique) (ASCO)

American Society of Clinical Oncology (Société américaine d’oncologie clinique) (ASCO)

June 2022 (Chicago, Illinois, USA)

Résumés

A phase 2 expanded access study of zanubrutinib (ZANU) in patients (pts) with Waldenström Macroglobulinemia (WM) ASPEN: long-term follow-up results of a phase 3 randomized trial of zanubrutinib (ZANU) vs ibrutinib (IBR) in patients with Waldenström macroglobulinemia (WM) AdvanTIG-206: anti-TIGIT monoclonal antibody (mAb) ociperlimab (BGB-A1217; OCI) plus anti-programmed cell death protein 1 (PD-1) mAb tislelizumab (TIS) plus BAT1706 versus TIS plus BAT1706 as first-line (1L) treatment for advanced hepatocellular carcinoma (HCC) Clinical outcomes associated with tislelizumab in patients (pts) with advanced hepatocellular carcinoma (HCC) who have been previously treated with sorafenib (SOR) or lenvatinib (LEN) in RATIONALE-208 Clinical outcomes in patients (pts) with previously treated advanced hepatocellular carcinoma (HCC) experiencing hepatitis B virus (HBV) DNA increases during tislelizumab (TIS) treatment in RATIONALE-208 Efficacy of first-line treatment for chronic lymphocytic leukemia: a Bayesian network meta-analysis Network meta-analysis of progression free survival in the treatment of relapsed or refractory chronic lymphocytic leukemia Population-wide patterns of care in chronic lymphocytic leukemia in Australia: an analysis of the pharmaceutical benefits scheme dataset Population-wide patterns of care in mantle cell lymphoma in Australia: an analysis of the pharmaceutical benefits scheme dataset Randomized, phase 3 study of second-line tislelizumab versus chemotherapy in advanced or metastatic esophageal squamous cell carcinoma (ESCC), RATIONALE 302: Asia subgroup Real world evidence of impact of atrial fibrillation (AF) on clinical and economic outcomes in patients with chronic lymphocytic leukemia (CLL) Real-world (RW) treatment patterns and comparative effectiveness of Bruton tyrosine kinase inhibitors (BTKi) in patients (pts) with mantle cell lymphoma (MCL) Real-world treatment (tx) patterns and economic burden of patients (pts) with marginal zone lymphoma (MZL) Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC, RATIONALE 302): impact on health-related quality of life (HRQoL) Tislelizumab, a PD-1 inhibitor for relapsed/refractory mature T/NK-cell neoplasms: results from a phase 2 study Updated analysis from a phase 2 study of tislelizumab (TIS) monotherapy in patients (pts) with previously treated, locally advanced, unresectable/metastatic microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) solid tumors Zanidatamab (zani), a HER2-targeted bispecific antibody, in combination with chemotherapy (chemo) and tislelizumab (TIS) as first line (1L) therapy for patients (pts) with advanced HER2-positive gastric/gastroesophageal junction adenocarcinoma (G/GEJC): preliminary results from a phase 1b/2 study Zanidatamab (zani), a HER2-targeted bispecific antibody, in combination with docetaxel as first-line (1L) therapy for patients (pts) with advanced HER2-positive breast cancer: preliminary results from a phase 1b/2 study Zanubrutinib plus obinutuzumab (ZO) versus obinutuzumab (O) monotherapy in patients (pts) with relapsed or refractory (R/R) follicular lymphoma (FL): primary analysis of the phase 2 randomized ROSEWOOD trial
Mai 2022

International Society for Pharmacoeconomics and Outcomes Research - Europe (Société internationale de recherche en pharmacoéconomie et les résultats) (ISPOR-EU)

Mai 2022

International Conference on Clinical and Experimental Hematology (Conférence internationale sur l'hématologie clinique et expérimentale) (ICCEH)

Avril 2022

Transplantation & Cellular Therapy (Greffe et thérapie cellulaire) (TCT)

Avril 2022

American Society of Clinical Oncology (Société américaine d’oncologie clinique) (ASCO) Plenary Series Program

Avril 2022

American Association for Cancer Research (Association américaine de recherche sur le cancer) (AACR)

American Association for Cancer Research (Association américaine de recherche sur le cancer) (AACR)

April 2022 (New Orleans, Louisiana, USA)
Avril 2022

British Society for Haematology (Société britannique d’hématologie) (BSH)

MARS 2022

Italian Society of Experimental Hematology (Société italienne d’hématologie expérimentale) (SIES)

MARS 2022

Korean Society of Hematology (Société coréenne d'hématologie) (KSH)

MARS 2022

European Lung Cancer Congress (Congrès européen pour le cancer du poumon) (ELCC)

MARS 2022

French Society of Hematology (Société française d’hématologie) (SFH)

MARS 2022

Society of Gynecologic Oncology (Société d’oncologie gynécologique) (SGO)

MARS 2022

Francophone Days of Hepato-gastroenterology and Digestive Oncology (Journées francophones d’hépato-gastroentérologie et d’oncologie digestive) (JFHOD)

Francophone Days of Hepato-gastroenterology and Digestive Oncology (Journées francophones d’hépato-gastroentérologie et d’oncologie digestive) (JFHOD)

Mars 2022 (Paris, France)
MARS 2022

European Society of Medical Oncology Targeted Anticancer Therapies (Société européenne d’oncologie médicale, thérapies anticancéreuses ciblées) (ESMO-TAT)

Février 2022

Japanese Society of Medical Oncology (Société japonaise d’oncologie médicale) (JSMO)

Janvier 2022

British Thoracic Oncology Group (groupe d’oncologie thoracique britannique) (BTOG)

Janvier 2022

American Society of Clinical Oncology - Gastrointestinal Cancers Symposium (Société américaine d’oncologie clinique - Symposium des cancers gastro-intestinaux) (ASCO-GI)

American Society of Clinical Oncology - Gastrointestinal Cancers Symposium (Société américaine d’oncologie clinique - Symposium des cancers gastro-intestinaux) (ASCO-GI)

January 2022 (San Francisco, California, USA)

Posters

AdvanTIG-203: a randomized phase 2 study comparing anti-TIGIT monoclonal antibody ociperlimab plus tislelizumab vs tislelizumab plus placebo as second-line treatment in patients with advanced or recurrent esophageal squamous cell carcinoma expressing programmed death-ligand 1 (PD-L1) AdvanTIG-206: anti-TIGIT monoclonal antibody ociperlimab + anti-PD-1 monoclonal antibody tislelizumab + BAT1706 vs tislelizumab + BAT1706 as first-line treatment for unresectable hepatocellular carcinoma Clinical outcomes associated with tislelizumab in patients with advanced hepatocellular carcinoma who have been previously treated with sorafenib or lenvatinib in RATIONALE-208 Clinical outcomes in patients with previously treated advanced hepatocellular carcinoma experiencing hepatitis B virus DNA increases during tislelizumab treatment in RATIONALE-208 DKN-01 and tislelizumab ± chemotherapy as first-line (1L) or second-line (2L) investigational therapy in advanced gastroesophageal adenocarcinoma (GEA): DisTinGuish trial Randomized, phase 3 study of second-line tislelizumab versus chemotherapy in advanced or metastatic esophageal squamous cell carcinoma, RATIONALE 302: Asia subgroup Safety, tolerability, and preliminary antitumor activity of sitravatinib plus tislelizumab in patients with unresectable locally advanced or metastatic gastric cancer/gastroesophageal junction cancer Safety, tolerability, and preliminary antitumor activity of sitravatinib plus tislelizumab in patients with unresectable locally advanced or metastatic hepatocellular carcinoma Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC, RATIONALE 302): impact on health-related quality of life Updated analysis from a phase 2 study of tislelizumab monotherapy in patients with previously treated, locally advanced unresectable or metastatic microsatellite instability-high or mismatch repair-deficient solid tumors

Résumés

AdvanTIG-203: a randomized phase 2 study comparing anti-TIGIT ociperlimab plus tislelizumab vs tislelizumab plus placebo as second-line treatment in patients with advanced or recurrent esophageal squamous cell carcinoma (ESCC) expressing programmed death-ligand 1 (PD-L1) AdvanTIG-206: anti-TIGIT monoclonal antibody (mAb) ociperlimab (BGB-A1217; OCI) plus anti-programmed cell death protein-1 (PD-1) mAb tislelizumab (TIS) plus BAT1706 vs TIS plus BAT1706 as first-line treatment for advanced hepatocellular carcinoma (HCC) Clinical outcomes associated with tislelizumab in patients (pts) with advanced hepatocellular carcinoma (HCC) who have been previously treated with sorafenib (SOR) or lenvatinib (LEN) in RATIONALE-208 Clinical outcomes in patients (pts) with previously treated advanced hepatocellular carcinoma (HCC) experiencing hepatitis B virus (HBV) DNA increases during tislelizumab (TIS) treatment in RATIONALE-208 DKN-01 and tislelizumab ± chemotherapy as first-line (1L) or second-line (2L) investigational therapy in advanced gastroesophageal adenocarcinoma (GEA): DisTinGuish trial Randomized, phase 3 study of second-line tislelizumab vs chemotherapy in advanced or metastatic esophageal squamous cell carcinoma, RATIONALE 302: Asia subgroup Safety, tolerability, and preliminary antitumor activity of sitravatinib plus tislelizumab (TIS) in patients (pts) with unresectable locally advanced or metastatic gastric cancer/gastroesophageal junction cancer (GC/GEJC) Safety, tolerability, and preliminary antitumor activity of sitravatinib plus tislelizumab (TIS) in patients (pts) with unresectable locally advanced or metastatic hepatocellular carcinoma (HCC) Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC, RATIONALE 302): impact on health-related quality of life (HRQoL) Updated analysis from a phase 2 study of tislelizumab (TIS) monotherapy in patients (pts) with previously treated, locally advanced, unresectable/metastatic microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) solid tumors
Décembre 2021

American Society of Hematology (Société américaine d’hématologie) (ASH)

American Society of Hematology (Société américaine d’hématologie) (ASH)

Décembre 2021 (Atlanta, Géorgie, États-Unis)

Présentations

Factors associated with treatment among older adults diagnosed with chronic lymphocytic leukemia: an analysis using Medicare claims data Impact of atrial fibrillation on cardiovascular and economic outcomes in patients with chronic lymphocytic leukemia Phase 2 study of zanubrutinib in BTK inhibitor-intolerant patients with relapsed/refractory B-cell malignancies Preliminary safety and efficacy data from patients with relapsed/refractory B-cell malignancies treated with the novel B-cell lymphoma 2 (BCL2) inhibitor BGB-11417 in monotherapy or in combination with zanubrutinib Productivity loss and indirect costs among non-Hodgkin lymphoma patients and their caregivers Real-world Bruton tyrosine kinase inhibitor treatment patterns, compliance, costs, and hospitalizations in patients with mantle cell lymphoma in the United States Real-world disease burden, costs and resource utilization of hospital-based care among mantle cell lymphoma, Waldenström macroglobulinemia, marginal zone lymphoma and chronic lymphocytic leukemia: disparities and risk factors Real-world testing patterns for risk assessment and implications on the adoption of novel therapeutics in chronic lymphocytic leukemia: IGHV mutation status, FISH cytogenetic, and immunophenotyping Real-world treatment patterns, adherence and healthcare resource utilization for chronic lymphocytic leukemia/small lymphocytic lymphoma among veterans in the United States SEQUOIA: results of a phase 3 randomized study of zanubrutinib versus bendamustine + rituximab in patients with treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma Zanubrutinib in combination with venetoclax for patients with treatment-naive chronic lymphocytic leukemia or small lymphocytic lymphoma with del(17p): early results from Arm D of the SEQUOIA (BGB-3111-304) trial

Résumés

Factors associated with treatment among older adults diagnosed with chronic lymphocytic leukemia: an analysis using Medicare claims data Impact of atrial fibrillation on cardiovascular and economic outcomes in patients with chronic lymphocytic leukemia Phase 2 study of zanubrutinib in BTK inhibitor-intolerant patients (pts) with relapsed/refractory B-cell malignancies Preliminary safety and efficacy data from patients (pts) with relapsed/refractory (R/R) B-cell malignancies treated with the novel B-cell lymphoma 2 (BCL2) inhibitor BGB-11417 in monotherapy or in combination with zanubrutinib Productivity loss and indirect costs among non-Hodgkin lymphoma patients and their caregivers Real-world Bruton tyrosine kinase inhibitor treatment patterns, compliance, costs, and hospitalizations in patients with mantle cell lymphoma in the United States Real-world disease burden, costs and resource utilization of hospital-based care among mantle cell lymphoma, Waldenstrӧm macroglobulinemia, marginal zone lymphoma and chronic lymphocytic leukemia: disparities and risk factors Real-world testing patterns for risk assessment and implications on the adoption of novel therapeutics in chronic lymphocytic leukemia: IGHV mutation status, FISH cytogenetic, and immunophenotyping Real-world treatment patterns, adherence and healthcare resource utilization for chronic lymphocytic leukemia/small lymphocytic lymphoma among veterans in the United States SEQUOIA: results of a phase 3 randomized study of zanubrutinib versus bendamustine + rituximab (BR) in patients with treatment-naïve (TN) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) Zanubrutinib in combination with venetoclax for patients with treatment-naïve (TN) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) with del(17p): early results from Arm D of the SEQUOIA (BGB-3111-304) trial
Décembre 2021

European Society of Medical Oncology Immuno-Oncology (Société européenne d’oncologie médicale et d’immuno-oncologie) (ESMO-IO)

European Society of Medical Oncology Immuno-Oncology (Société européenne d’oncologie médicale et d’immuno-oncologie) (ESMO-IO)

Décembre 2021 (Genève, Suisse)
Décembre 2021

Immunotherapy Bridge (IBC)

Novembre 2021

International Society for Pharmacoeconomics and Outcomes Research - Europe (Société internationale de recherche en pharmacoéconomie et les résultats - Europe) (ISPOR-EU)

Novembre 2021

Australasian Melanoma Conference (Conférence australasienne sur le mélanome) (AMC)

Novembre 2021

Clinical Oncology Society of Australia (Société d’oncologie clinique d’Australie) (COSA)

Novembre 2021

Portuguese Society of Hematology (Société portugaise d’hématologie) (SPH)

Novembre 2021

Society for Immunotherapy of Cancer (Société d’immunothérapie pour le cancer) (SITC)

Octobre 2021

Italian Society of Hematology (Société italienne d’hématologie) (SIE)

Octobre 2021

Academy of Managed Care Pharmacy Nexus (Nexus Académie de gestion pharmaceutique des soins) (AMCP Nexus)

Octobre 2021

Spanish Society of Medical Oncology (Société espagnole d’oncologie médicale) (SEOM)

Octobre 2021

Spanish Society of Hematology and Hemotherapy (Société espagnole d’hématologie et d’hématothérapie) (SEHH)

Octobre 2021

Australasian Gastro-Intestinal Trials Group (Groupe australasien d’essais gastro-intestinaux) (AGITG)

Octobre 2021

German, Austrian, and Swiss Societies for Hematology & Medical Oncology (Sociétés allemandes, autrichiennes et suisses d’hématologie et d’oncologie médicale) (DGHO)

Septembre 2021

Society of Hematologic Oncology (Société d’oncologie hématologique) (SOHO)

Septembre 2021

Hematology Society of Australia and New Zealand (Blood) [Société d’hématologie d’Australie et de Nouvelle Zélande (sang)]

Hematology Society of Australia and New Zealand (Blood) [Société d’hématologie d’Australie et de Nouvelle Zélande (sang)]

Septembre 2021 (virtuel)
Septembre 2021

European Society for Medical Oncology (Société européenne d’oncologie médicale) (ESMO)

European Society for Medical Oncology (Société européenne d’oncologie médicale) (ESMO)

Septembre 2021 (virtuel)
Septembre 2021

International Workshop on CLL (Atelier international sur la leucémie lymphoïde chronique) (iwCLL)

Septembre 2021

Chinese Society of Clinical Oncology (Société chinoise d’oncologie clinique) (CSCO)

Chinese Society of Clinical Oncology (Société chinoise d’oncologie clinique) (CSCO)

Septembre 2021 (virtuel)

Résumés

A phase 2 study of tislelizumab monotherapy in patients with previously treated, locally advanced, unresectable or metastatic microsatellite instability-high/mismatch repair-deficient solid tumors A phase II study of the efficacy and safety of tislelizumab plus lenvatinib in patients with advanced or metastatic hepatocellular carcinoma: results of safety run-in period First interim analysis of ALPINE study: results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma Phase 2 study of zanubrutinib in patients with relapsed/refractory marginal zone lymphoma (MAGNOLIA study) Preliminary results of the phase 2 study of zanubrutinib in patients with previously treated B-cell malignancies intolerant to ibrutinib and/or acalabrutinib RATIONALE 302: randomized, phase 3 study of tislelizumab vs chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma RATIONALE-307: tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced squamous NSCLC in patients aged ≥ 65 years Results from RATIONALE 303: a global phase 3 study of tislelizumab (TIS) vs docetaxel (TAX) as second- or third-line therapy for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) Safety/tolerability and preliminary antitumor activity of sitravatinib plus tislelizumab in patients with PD-(L)1-refractory/resistant unresectable or metastatic melanoma from a phase 1b study Safety/tolerability and preliminary antitumor activity of sitravatinib plus tislelizumab in patients with advanced platinum-resistant ovarian cancer (PROC) Tislelizumab (BGB-A317) for relapsed/refractory classical Hodgkin lymphoma: long-term follow-up efficacy and safety results from a phase 2 study Zanidatamab (ZW25), a novel anti-HER2 bispecific antibody, monotherapy as second-line treatment for patients (pts) with advanced or metastatic HER2-amplified biliary tract cancer (BTC): a phase 2b trial-in-progress Zanubrutinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia: 34-month follow-up results
Septembre 2021

French Society of Hematology (Société française d’hématologie) (SFH)

Septembre 2021

World Congress on Lung Cancer (Congrès mondial sur le cancer du poumon) (WCLC)

Septembre 2021

Polish Society of Hematology and Transfusion Medicine (Société polonaise d’hématologie et de médecine transfusionnelle) (PTHiT)

Août 2021

Pan Pacific Lymphoma Conference (Conférence pan-Pacifique du lymphome) (PPLC)

Juillet 2021

International Symposium of Yonsei Song-dang Institute for Cancer Research (Symposium international de l’Institut Yonsei Song-dang de recherche sur le cancer) (N/A)

International Symposium of Yonsei Song-dang Institute for Cancer Research (Symposium international de l’Institut Yonsei Song-dang de recherche sur le cancer) (N/A)

Juillet 2021 (Séoul, Corée du Sud)
Juin 2021

World Congress on Gastrointestinal Cancer (Congrès mondial sur le cancer gastrointestinal) (WCGI)

Juin 2021

International Conference on Malignant Lymphoma (Conférence internationale sur le lymphome malin) (ICML)

Juin 2021

European Hematology Association (Association européenne d’hématologie) (EHA)

European Hematology Association (Association européenne d’hématologie) (EHA)

Juin 2021 (virtuel)
Juin 2021

American Society of Clinical Oncology (Société américaine d’oncologie clinique) (ASCO)

American Society of Clinical Oncology (Société américaine d’oncologie clinique) (ASCO)

Juin 2021 (virtuel)

Posters

A phase 2 study of pamiparib in the treatment of patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutation A phase 2 study of tislelizumab monotherapy in patients with previously treated, locally advanced unresectable or metastatic microsatellite instability-high/mismatch repair deficient solid tumors ADVANTIG-105: phase 1 dose-escalation study of anti-TIGIT monoclonal antibody ociperlimab (BGB-A1217) in combination with tislelizumab in patients with advanced solid tumors AdvanTIG-202: a phase 2 study investigating anti-TIGIT monoclonal antibody ociperlimab plus anti-PD-1 monoclonal antibody tislelizumab in patients with previously treated recurrent or metastatic cervical cancer AdvanTIG-203: a randomized phase 2 study comparing anti-TIGIT monoclonal antibody ociperlimab plus tislelizumab vs tislelizumab plus placebo as second-line treatment in patients with advanced or recurrent esophageal squamous cell carcinoma expressing programmed death-ligand 1 (PD-L1) AdvanTIG-302: anti-TIGIT monoclonal antibody ociperlimab plus tislelizumab vs pembrolizumab in programmed death ligand 1-selected, previously untreated, locally advanced, unresectable or metastatic non-small cell lung cancer Efficacy and safety of zanubrutinib versus rituximab-based chemotherapy in Waldenstrӧm macroglobulinemia (WM): matching-adjusted indirect comparisons PARALLEL 303: phase 2 randomized study of pamiparib vs placebo as maintenance therapy in patients with inoperable locally advanced or metastatic gastric cancer that responded to platinum-based first-line chemotherapy RATIONALE 302: randomized, phase 3 study of tislelizumab vs chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma RATIONALE-307: tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced squamous NSCLC in patients aged ≥ 65 The effects of tislelizumab treatment on the health-related quality of life of non−small cell lung cancer patients who progressed on a prior platinum-containing regimen Zanidatamab, an anti-HER2 bispecific antibody, plus chemotherapy with/without tislelizumab as first-line treatment for patients with advanced HER2-positive breast cancer or gastric/gastroesophageal junction adenocarcinoma: a phase 1B/2 trial-in-progress

Résumés

A phase 2 study of pamiparib in the treatment of patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutation A phase 2 study of tislelizumab monotherapy in patients with previously treated, locally advanced unresectable or metastatic microsatellite instability-high/mismatch repair deficient solid tumors AdvanTIG-105: phase 1 dose-escalation study of anti-TIGIT monoclonal antibody ociperlimab (BGB-A1217) in combination with tislelizumab in patients with advanced solid tumors AdvanTIG-202: a phase 2 study investigating anti-TIGIT monoclonal antibody ociperlimab plus anti-PD-1 monoclonal antibody tislelizumab in patients with previously treated recurrent or metastatic cervical cancer AdvanTIG-203: a randomized phase 2 study comparing anti-TIGIT ociperlimab plus tislelizumab vs tislelizumab plus placebo as second-line treatment in patients with advanced or recurrent esophageal squamous cell carcinoma (ESCC) expressing programmed death-ligand 1 (PD-L1) AdvanTIG-302: anti-TIGIT monoclonal antibody (mAb) ociperlimab (OCI) plus tislelizumab (TIS) vs pembrolizumab (PEM) in programmed death ligand 1 (PD-L1) selected, previously untreated, locally advanced, unresectable or metastatic non-small cell lung cancer (NSCLC) Cardiac risk factors and adverse events among patients receiving first-line CLL treatment in a real-world community practice setting Cost-effectiveness of zanubrutinib versus ibrutinib in adult patients with Waldenström macroglobulinemia in the United States